Page last updated: 2024-12-09

2-(1H-benzimidazol-2-ylmethyl)benzene-1,4-diol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

2-(1H-benzimidazol-2-ylmethyl)benzene-1,4-diol, also known as **2-(1H-benzimidazol-2-ylmethyl)hydroquinone** or **BBH**, is a **small molecule** with a **complex structure** that combines a **benzimidazole** ring with a **hydroquinone** moiety.

**Structure:**

* **Benzimidazole ring:** A nitrogen-containing heterocyclic ring system, common in many bioactive molecules.
* **Hydroquinone:** A benzene ring with two hydroxyl groups (-OH), known for its antioxidant properties.
* **Linkage:** A methylene group (-CH2-) connects the benzimidazole and hydroquinone rings.

**Importance in Research:**

BBH is a molecule of interest in research due to its potential applications in various fields:

**1. Antioxidant Activity:**
* The hydroquinone group is known to scavenge free radicals, contributing to the antioxidant activity of BBH.
* This antioxidant potential has been investigated for its role in preventing oxidative stress and its potential for applications in treating diseases associated with oxidative damage.

**2. Antimicrobial Activity:**
* Benzimidazole derivatives are known to exhibit antimicrobial properties, targeting various bacterial and fungal species.
* BBH has shown promising activity against some bacterial strains, suggesting its potential as a lead compound for developing new antibiotics.

**3. Anti-Cancer Activity:**
* Some studies have investigated the potential of BBH as an anticancer agent.
* The benzimidazole ring structure can interact with DNA, potentially inhibiting cell proliferation and inducing apoptosis.

**4. Other Potential Applications:**
* BBH has also been explored for its potential in other areas, including:
* **Neuroprotection:** Its antioxidant properties might offer protection against neurodegenerative diseases.
* **Anti-inflammatory Activity:** BBH has shown some anti-inflammatory effects in preclinical studies.

**Key Points:**

* BBH is a complex molecule with potential biological activity.
* The combination of a benzimidazole and hydroquinone moiety contributes to its diverse biological actions.
* Research into BBH is ongoing to explore its full therapeutic potential in various disease areas.

**Further Research:**

* More in-depth studies are needed to understand the exact mechanisms of action of BBH and optimize its pharmacological properties for clinical applications.
* Further research is also required to evaluate its safety and efficacy in preclinical and clinical trials.

Cross-References

ID SourceID
PubMed CID882243
CHEMBL ID1376835
CHEBI ID114796
SCHEMBL ID582154

Synonyms (23)

Synonym
AKOS002162073
HMS2638N24
IFLAB1_004015
2-(1h-benzimidazol-2-ylmethyl)-1,4-benzenediol
smr000298430
MLS000676416 ,
OPREA1_114011
OPREA1_021779
CHEBI:114796
HMS1423G11
2-(1h-benzimidazol-2-ylmethyl)benzene-1,4-diol
STK965302
HMS3359I15
SCHEMBL582154
LGDLZQUSAVSGIM-UHFFFAOYSA-N
2-(1h-benzoimidazol-2-ylmethyl)benzene-1,4-diol
cid_882243
2-(1h-benzimidazol-2-ylmethyl)hydroquinone
bdbm80714
CHEMBL1376835
Q27196201
SR-01000446440-1
sr-01000446440
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzimidazolesAn organic heterocyclic compound containing a benzene ring fused to an imidazole ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (19)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency10.00000.631035.7641100.0000AID504339
LuciferasePhotinus pyralis (common eastern firefly)Potency21.33130.007215.758889.3584AID588342
WRNHomo sapiens (human)Potency55.32390.168331.2583100.0000AID651768; AID720497
phosphopantetheinyl transferaseBacillus subtilisPotency35.48130.141337.9142100.0000AID1490
GLS proteinHomo sapiens (human)Potency35.48130.35487.935539.8107AID624170
TDP1 proteinHomo sapiens (human)Potency18.64620.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency25.11890.180013.557439.8107AID1460
thioredoxin glutathione reductaseSchistosoma mansoniPotency6.30960.100022.9075100.0000AID485364
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency28.18380.707912.194339.8107AID720542
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency3.16230.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency6.80610.540617.639296.1227AID720503
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency3.54810.036619.637650.1187AID2100
chromobox protein homolog 1Homo sapiens (human)Potency2.51190.006026.168889.1251AID540317
huntingtin isoform 2Homo sapiens (human)Potency8.91250.000618.41981,122.0200AID1688
pyruvate kinase PKM isoform aHomo sapiens (human)Potency39.81070.04017.459031.6228AID1631; AID1634
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency15.84890.00798.23321,122.0200AID2551
gemininHomo sapiens (human)Potency29.09290.004611.374133.4983AID624296
lamin isoform A-delta10Homo sapiens (human)Potency35.48130.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
hexokinase HKDC1Homo sapiens (human)IC50 (µMol)5.24002.49007.744412.4000AID504729; AID504763
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]